Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price objective increased by equities research analysts at Canaccord Genuity Group from $28.00 to $38.00 in a report released on ...
Dr. Lokesh, Associate Professor in the Department of General Medicine in the Hassan Institute of Medical Sciences, was ...
Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shares were up 6.6% during trading on Tuesday after Canaccord Genuity Group raised their price target on the stock from $28.00 to $38.00.
Eleven cases of hypertrichosis — commonly known as “werewolf syndrome” — has developed in babies throughout Spain.
Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, is proud to announce its ...
The American Diabetes Association is advising doctors and patients not to use compounded GLP-1s due to uncertainty about their content, safety, ...
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...
This penchant for calls isn't entirely unusual, given the stock's 50-day call/put volume ratio of 3.55 at the International ...
Zscaler (ZS) stock is brushing off strong fiscal first-quarter results after also issuing a disappointing forecast ...
Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback